Biomarkers in Oncology Studies

The Science, the Medicine, and the Impact on Development

Craig Dorer-Abadia | Michael Murphy, MD, PhD | Gabriela Rosu MD | Matthew Confeld PharmD PhD

Biomarker development for oncology should integrate scientific, medical, and operational considerations. Recent advancements in discovery research for biomarkers further necessitate their integration and present implications for the operations of clinical trials. Read this white paper for an overview of oncology biomarker development, to discover the considerations for determining biomarkers in an early phase trial, for insight on collecting biomarker samples, and to understand the implications of biomarker selection on commercialization.

Your form has been successfully submitted! Click the button below to access.
Read more
Craig Dorer-Abadia
Meet the author

Craig Dorer-Abadia

Senior Director, Project Management, Oncology
Learn more
Michael Murphy, MD, PhD
Meet the author

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
Learn more